ANTIBODIES AGAINST SIGLEK-15 FOR TREATMENT OF DISEASE CONNECTED WITH BONE MASS LOSS

摘要

1. An isolated antibody or antigen-binding fragment capable of binding to a polypeptide capable of activating the differentiation of osteoclasts and which is at least 80% identical to amino acids at positions 20-259 in the sialosigning lectin of the immunoglobulin superfamily 15 (Siglec-15; SEQ ID NO: 2), while the specified antibody or antigen-binding fragment is able to inhibit the differentiation of osteoclasts, bone resorption or is able to block the binding of Siglec-15 with sialic acid. 2. An isolated antibody or antigen binding fragment according to claim 1, characterized in that the isolated antibody or antigen binding fragment is capable of inhibiting the differentiation of osteoclast progenitor cells into differentiated osteoclasts. An isolated antibody or antigen binding fragment according to claim 2, characterized in that the isolated antibody or antigen binding fragment is a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a humanized antibody, a human antibody, or a fragment thereof. An isolated antibody or antigen-binding fragment containing: a) 3 regions of the CDRs of the variable domain of the light chain with the sequence of SEQ ID NO: 66, and 3 regions of the CDRs of the variable domain of the heavy chain with the sequence of SEQ ID NO: 68; or b) the variable domain of the light chain, which is at least 70% identical to the sequence of SEQ ID NO: 66, and the variable domain of the heavy chain, which is at least 70% identical to the sequence of SEQ ID NO: 68.5. An isolated antibody or antigen binding fragment capable of specifically binding to SEQ ID NO: 2 or a variant thereof that is at least 80% identical